Press

PharmAla Biotech (CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of both GMP LaNeo™ MDMA and Engineering MDMA to InterVivo Solutions (Toronto), its client companies and Affiliates. InterVivo Solutions is a well-established pre-clinical contract research organization (CRO) with expertise in neuropsychiatric and neurological diseases. Together with Transpharmation, they form the largest boutique neuroscience-specialized in vivo CRO. “We’re pleased to be able to offer our global client base a reliable and high-quality supply of reference MDMA through this exclusive supply agreement with PharmAla. Our hope is this will streamline and further propel our client’s…

REVITALIST LIFESTYLE AND WELLNESS LTD. (CSE: CALM | OTCQB: RVLWF | FSE: 4DO), one of the largest publicly listed US based ketamine wellness clinics, is pleased to report continued expansion of service lines offering an online vitamin supplement line, an online global curriculum, and an onsite and virtual training program for providers and therapists creating a quality ecosystem for everyone entering the psychedelic wellness space. Vital+® is a proprietary supplement line that has been created to optimally complement the nutritional needs of individuals for improved mental wellness. The combination of vitamins and adaptogenic ingredients complement the body and brain’s needs with…

 Optimi Health Corp. (CSE: OPTI | OTCQX: OPTHF | FRA: 8BN), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a partnership with psilocybin patient advocate, Thomas Hartle. The parties have agreed to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients. “Honouring Thomas’s incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever,” “We share Thomas’s…

Cybin Inc. (NEO: CYBN | NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, today reported unaudited financial results for its first quarter ended June 30, 2022 and recent business highlights. “Looking back at the last 12 months, we have made positive progress toward our goal of advancing psychedelics to therapeutics. In that time, we have moved from the lab to the clinic where we now have two major development programs underway,” said Doug Drysdale, Chief Executive Officer of Cybin.” “Our lead candidate CYB003 is the first novel psilocybin analog to be evaluated in a Phase 1/2a trial…

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) completed the acquisition of two ketamine clinics in Georgia through an asset purchase of Invictus Clinics, LLC, which will be brought into the fast-growing national chain of psychedelic mental-health facilities. The clinics are located in Atlanta and Woodstock, Ga., operated under the name of the Invictus Clinic. They offer ketamine-assisted therapy, hydration via IV infusion as well as NAD+. They join Irwin Naturals Emergence, a national chain of mental-health facilities providing cutting-edge care behind a truly household brand name that is recognized in 80 percent of U.S. homes.1 “The vision we laid out for…